8-K: Insmed Reports Strong 2025 Revenues, Advances Pipeline

Insmed announced preliminary unaudited full-year 2025 revenues exceeding expectations for ARIKAYCE and a robust BRINSUPRI launch, alongside significant clinical program advancements and upcoming catalysts.

Summary

• Insmed reported preliminary unaudited global revenues of approximately $606.4 million for full-year 2025, a 67% increase from $363.7 million in 2024.
• ARIKAYCE global revenues for full-year 2025 were approximately $433.8 million, exceeding the upper end of the company's guidance range and representing a 19% increase over 2024.
• BRINSUPRI, in its first full quarter of launch (Q4 2025), generated approximately $144.6 million in U.S. revenues, contributing to a full-year 2025 U.S. total of approximately $172.7 million.
• Approximately 4,000 medical professionals had prescribed BRINSUPRI by year-end 2025, with about 9,000 new patients starting therapy in Q4 2025 alone.
• The company anticipates 2026 global ARIKAYCE revenues to be between $450 million and $470 million.
• Topline data from the Phase 3 ENCORE study of ARIKAYCE in MAC lung disease is now anticipated in March or April of 2026.
• Topline data from the Phase 2b CEDAR study of brensocatib in hidradenitis suppurativa (HS) is now anticipated in the second quarter of 2026.
• Insmed initiated the Phase 3 PALM-ILD study of TPIP in PH-ILD in Q4 2025 and plans to initiate additional Phase 3 studies for TPIP in PAH, PPF, and IPF in 2026.
• The company acquired INS1148, a Phase 2-ready monoclonal antibody, in December 2025, with plans to advance development in interstitial lung disease and moderate-to-severe asthma.
• Insmed is advancing multiple gene therapy candidates (INS1201 for DMD, INS1202 for ALS, INS1203 for Stargardt disease) and other immunology programs (INS1033 for RA and IBD) with several IND filings expected in 2026.

Sentiment

Score: 8

Explanation: The company demonstrated strong commercial performance with both its key products, exceeding revenue guidance for ARIKAYCE and showing a robust initial launch for BRINSUPRI. The pipeline is rich with multiple late-stage clinical catalysts and new programs, including gene therapies and a recent acquisition, indicating significant future growth potential. The overall momentum and strategic expansion into new therapeutic areas are highly positive.

Positives

• ARIKAYCE global revenues of $433.8 million for full-year 2025 exceeded the upper end of the company's guidance range.
• BRINSUPRI demonstrated a strong initial launch with approximately $144.6 million in U.S. revenues in its first full quarter (Q4 2025) and 9,000 new patient starts.
• BRINSUPRI received European Commission approval in November 2025 for NCFB, with EU launch planned for H1 2026 and UK/Japan launches pending approval in 2026.
• The company initiated the Phase 3 PALM-ILD study for TPIP and plans to initiate three more Phase 3 studies for TPIP in PAH, PPF, and IPF in 2026, indicating a robust late-stage pipeline.
• The acquisition of INS1148, a Phase 2-ready monoclonal antibody, expands the pipeline in respiratory and immunology/inflammation.
• The Independent Data Monitoring Committee (IDMC) recommended advancing dosing in the Phase 1 ASCEND study for INS1201 (DMD), indicating positive early progress for the gene therapy program.
• Insmed's total revenues for full-year 2025 grew by 67% globally and 78% in the U.S. compared to 2024.

Negatives

• Approximately 9% of BRINSUPRI's Q4 2025 revenues were attributed to inventory stocking, which may not reflect ongoing demand.
• The company expects out-of-pocket reset dynamics in Q1 2026 and anticipates increased rebating and stricter access criteria as payor contracts for BRINSUPRI are finalized in 2026.

Risks

• Failure to continue successful commercialization of ARIKAYCE or BRINSUPRI, or to maintain regulatory approvals.
• Inability to obtain full FDA approval for ARIKAYCE or expand its indication to a broader patient population.
• Delays in obtaining regulatory approvals for product candidates in the U.S., Europe, or Japan.
• Uncertainties or changes in market acceptance of marketed products or product candidates by physicians, patients, and payors.
• Inability to obtain and maintain adequate reimbursement or acceptable prices for products.
• Inaccuracies in estimates of market size, patient uptake, treatment duration, or adherence rates.
• Failure of third parties to manufacture sufficient quantities of products or conduct clinical trials.
• Inability to maintain compliance with covenants in senior secured loan and royalty financing agreements.
• Failure to successfully conduct future clinical trials, enroll sufficient patients, or generate necessary data for regulatory approval.
• Development of unexpected safety or efficacy concerns related to marketed products or product candidates.
• Risks that clinical studies will be delayed, serious side effects identified, or protocol amendments rejected.
• Failure to successfully predict the time and cost of development, regulatory approval, and commercialization for novel gene therapy products.
• Risk that interim, topline, or preliminary data from clinical trials may change or be interpreted differently with additional data.
• Risk that competitors may obtain orphan drug exclusivity for similar products.
• Inability to attract and retain key personnel or effectively manage growth.
• Inability to successfully integrate acquisitions or ensure their commercial success.
• Inability to adapt to a highly competitive and changing environment.
• Risk that government healthcare legislation or other government action materially increases costs.
• Business or economic disruptions due to catastrophes, natural disasters, or public health crises.
• Risk that current and potential future use of AI and machine learning may not be successful.
• Deterioration in general economic conditions, including prolonged periods of inflation.
• Involvement in costly intellectual property disputes or inability to adequately protect intellectual property rights.
• Restrictions or obligations imposed by license agreements with PARI and AstraZeneca AB.
• Cost and potential reputational damage from litigation, including product liability claims.
• Risk of material disruption due to a cybersecurity attack or issue.
• Changes in laws and regulations applicable to the business, including pricing reform.
• History of operating losses and the possibility of never achieving or maintaining profitability.
• Goodwill impairment charges affecting results of operations and financial condition.
• Inability to repay existing indebtedness and uncertainties regarding access to future capital.
• Delays in the execution of plans to build out an additional third-party manufacturing facility.

Future Outlook

The company's Chair and CEO, Will Lewis, stated that while 2025 was a landmark year, the road ahead is poised to be even more exciting. With numerous upcoming clinical and commercial catalysts across its designated therapeutic areas (Respiratory, Immunology & Inflammation, and Neuro & Other Rare), the company believes the next 18 months could accelerate its trajectory further and bring it closer to helping more patients with serious diseases. The company anticipates submitting an average of one to two Investigational New Drug (IND) applications per year from its pre-clinical research programs.

Management Comments

• "2025 was a landmark year for the patients we serve, our company, and our people, during which we demonstrated what's possible when breakthrough science meets steadfast execution."
• "Our strong BRINSUPRI launch and encouraging TPIP readout in PAH reinforced both the clinical potential of our growing portfolio and the remarkable discipline of our teams."
• "As monumental as this past year was, the road ahead is poised to be even more exciting. With numerous upcoming clinical and commercial catalysts across our designated therapeutic areas – Respiratory, Immunology & Inflammation, and Neuro & Other Rare – we believe that the next 18 months could accelerate our trajectory even further and bring us closer to helping more patients living with serious diseases."

Industry Context

Insmed operates within the highly competitive biopharmaceutical industry, focusing on developing firstand best-in-class therapies for serious diseases, particularly in rare and orphan indications. The company's strategy involves expanding its commercial footprint for approved products like ARIKAYCE and BRINSUPRI, while simultaneously advancing a diverse pipeline across respiratory, immunology & inflammation, and neuro & other rare diseases. This includes small molecules, monoclonal antibodies, and cutting-edge gene therapies, reflecting broader industry trends towards precision medicine and advanced therapeutic modalities. The strong performance of ARIKAYCE and the successful launch of BRINSUPRI position Insmed as a significant player in the rare disease space, particularly in lung conditions.

Comparison to Industry Standards

• NA

Stakeholder Impact

• **Shareholders:** Positive financial results, exceeding guidance, and a robust pipeline with multiple upcoming catalysts are likely to enhance shareholder value and confidence.
• **Patients:** Advancements in clinical programs for ARIKAYCE, BRINSUPRI, TPIP, and gene therapies offer potential new or expanded treatment options for serious and rare diseases.
• **Employees:** Strong company performance and growth, coupled with recognition as a top employer, likely contribute to employee morale and retention.
• **Healthcare Providers:** New product approvals and expanded indications provide additional tools for managing complex patient conditions like NCFB and MAC lung disease.
• **Payors:** The company's engagement with payors to establish access requirements and manage rebating will impact the cost and coverage of its therapies.

Next Steps

• Report final and complete fourth-quarter and full-year 2025 financial results in February 2026.
• Launch BRINSUPRI in the European Union in the first half of 2026.
• Launch BRINSUPRI in the United Kingdom and Japan in 2026, pending approval.
• Anticipate topline readout of the Phase 3 ENCORE trial for ARIKAYCE in March or April of 2026.
• Submit a supplementary new drug application (sNDA) to the U.S. FDA for ARIKAYCE in all patients with MAC lung disease in the second half of 2026, pending successful ENCORE results.
• Initiate a Phase 3 study of TPIP in patients with pulmonary arterial hypertension (PAH) in early 2026.
• Report data from the open-label extension (OLE) of the Phase 2b study of TPIP in PAH in the second half of 2026.
• Initiate additional Phase 3 studies of TPIP in progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF) in the second half of 2026.
• Advance Phase 2 development programs for INS1148 initially in interstitial lung disease and moderate-to-severe asthma.
• Anticipate reporting topline data from the Phase 2b CEDAR study of brensocatib in HS in the second quarter of 2026.
• File an IND for INS1033 (DPP1 inhibitor) in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) in 2026.
• Continue enrolling cohorts 2 and 3 in the Phase 1 ASCEND clinical study of INS1201 (DMD gene therapy).
• Continue the Phase 1 ARMOR study of INS1202 (ALS gene therapy).
• File an IND for INS1203 (Stargardt disease gene therapy) in 2026.
• Submit an average of one to two INDs per year from pre-clinical research programs.

Key Dates

Recommendation

Insmed has demonstrated exceptional commercial execution, with ARIKAYCE exceeding its full-year 2025 revenue guidance and BRINSUPRI showing a robust initial launch. The company's pipeline is rich with multiple late-stage clinical catalysts and promising new programs, including gene therapies and a recent acquisition, indicating strong future growth potential across diverse therapeutic areas. The strategic expansion, positive clinical progress, and solid financial position make Insmed a compelling investment opportunity for long-term growth.

Keywords

Insmed, biopharmaceutical, ARIKAYCE, BRINSUPRI, brensocatib, amikacin, NCFB, MAC lung disease, PH-ILD, PAH, TPIP, gene therapy, Duchenne muscular dystrophy, ALS, Stargardt disease, clinical trials, revenue, financial results, J.P. Morgan Healthcare Conference, immunology, inflammation, respiratory diseases